Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617890

— · B

72f9eb7f-d504-525d-b6d6-86740f5d6076

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.500
  • E2F_TARGETS+0.480
  • PROTEIN_SECRETION+0.390
  • MYC_TARGETS_V1+0.320
  • PANCREAS_BETA_CELLS+0.290
  • ANDROGEN_RESPONSE+0.270
  • ESTROGEN_RESPONSE_EARLY+0.260
  • TGF_BETA_SIGNALING+0.240
  • UV_RESPONSE_DN+0.230
  • MTORC1_SIGNALING+0.190

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.350
  • HEDGEHOG_SIGNALING-0.340
  • INTERFERON_GAMMA_RESPONSE-0.330
  • INFLAMMATORY_RESPONSE-0.300
  • COMPLEMENT-0.290
  • INTERFERON_ALPHA_RESPONSE-0.290
  • MYOGENESIS-0.290
  • IL6_JAK_STAT3_SIGNALING-0.270
  • IL2_STAT5_SIGNALING-0.260
  • P53_PATHWAY-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG775
mng-umap@100
——0.866
2TCGA-E2-A155-01A-11R-A12D-07
breast-umap@18
—B0.839
3MDT-AP-0155
medullo-epn-umap@date-based
MedMedulloblastoma0.826
4SRR33532819
breast-umap@18
—E0.812
5TCGA-A2-A1G4-01A-11R-A13Q-07
breast-umap@18
—B0.811
6TCGA-BH-A204-01A-11R-A157-07
breast-umap@18
—B0.809
7TCGA-A2-A25E-01A-11R-A169-07
breast-umap@18
—B0.803
8MBCProject_0946_T1_RNA
breast-umap@18
—C0.797
9SRR1797299
lung-landscapes@6
—cohortSC0.793
10GSM5359416
bladder-landscape@3
——0.792

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.500Inavolisib— uncovered
E2F_TARGETS0.480Inavolisib— uncovered
PROTEIN_SECRETION0.390Remibrutinib— uncovered
MYC_TARGETS_V10.320Inavolisib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
ANDROGEN_RESPONSE0.270Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.260Inavolisib— uncovered
TGF_BETA_SIGNALING0.240Inavolisib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
MTORC1_SIGNALING0.190Inavolisib— uncovered
MITOTIC_SPINDLE0.170Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.130Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.120Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.120Idelalisib— uncovered
SPERMATOGENESIS0.110Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.090Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.060Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.030Inavolisib— uncovered
FATTY_ACID_METABOLISM0.010Inavolisib— uncovered
PEROXISOME0.010Idelalisib— uncovered